NextCure, Inc. NXTC
Regular-session close
After hours · Nov 20, 6:42 PM ET
- YTD
- -54.55%
- 1 year
- -29.97%
5D +0.63 (+10.24%)
- Market cap
- 29.53M
- EPS (ttm)
- -6.80
- Shares out
- 28.01M
- Forward P/E
- -0.66
- YTD return
- -54.55%
- 1-year return
- -29.97%
- 50-day average
- 1.25
- 200-day average
- 1.49
- Volume
- 30.88K
- Avg volume
- 79.58K
- Open
- 6.60
- Previous close
- 6.78
- Day's range
- 6.45 – 6.96
- 52-week range
- 1.55 – 15.74
- Beta
- 0.79
- Price target
- 3.33 (-48.3%)
Key statistics
- Enterprise value
- -43.22M
- Price / book
- 0.23
- Free cash flow
- -26.33M
- Total cash
- 86.44M
- Total debt
- 6.29M
- Return on equity
- -54.74%
- Short % of float
- 0.28%
Fundamental scorecard
6 of 25 checks passed on NXTC’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.35 | -0.41 | -0.06 | -17.14% |
| Aug 1, 2024 | Jun 1, 2024 | -0.36 | -0.55 | -0.19 | -52.78% |
| Aug 1, 2024 | Jun 1, 2024 | -0.36 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.45 | -0.61 | -0.16 | -35.56% |
| May 2, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.54 | -0.52 | +0.02 | +3.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 2, 2024 | Needham | reit | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 3, 2024 | Needham | reit | Buy | Buy |
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nextcure.com
News
Your note
Sign in to keep a note on NXTC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 9.54% | 2,671,856 | 2.51M | Sep 29, 2024 |
| Logos Global Management LP | 8.93% | 2,500,000 | 2.35M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 8.22% | 2,302,598 | 2.17M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 4.07% | 1,141,200 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 3.53% | 987,324 | 929.07K | Sep 29, 2024 |
| Blackrock Inc. | 2.61% | 729,836 | 686.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.19% | 613,827 | 577.61K | Sep 29, 2024 |
| Federated Hermes MDT Mid Cap Growth Fund | 1.13% | 315,180 | 296.58K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 201,978 | 190.06K | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 0.61% | 171,519 | 161.40K | Jul 30, 2024 |
| BlackRock Advantage Small Cap Core Fund | 0.61% | 169,789 | 159.77K | Aug 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.54% | 150,000 | 141.15K | Sep 29, 2024 |
